



**World Health
Organization**

**Department of Immunization,
Vaccines and Biologicals (IVB)**

SAGE
meeting








SLIDE DECKS

**Strategic Advisory Group of Experts
on Immunization
31 March - 02 April 2020**







**Virtual meeting, WHO
Geneva, Switzerland**

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
31 March – 02 April 2020
Virtual Meeting
Draft agenda


Tuesday 31 March 2020

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	Opening – WHO/DDG S. JAKAB, Deputy Director-General Welcome – introduction of participants A. CRAVIOTO, Chair of SAGE.		10 min.
11:10	Global and Regional Reports - Session 1	FOR INFORMATION	1h 30 min.
	 Report from the Director of IVB. K. O'BRIEN. WHO. 20 min.		
	Updates from the Regions. 20 min.		
	 Update from Gavi. S. Berkley (TBC). 10 min.		
	 Modelling of COVID-19 epidemiology. K. Vandemaële. WHO. 10 min.		
	Discussion: 40 min.		
12:50	Break	Break	15 min.
13:05	Measles outbreak epidemiology and WHO coordination - Session 2	FOR DISCUSSION	1h
	 Response to measles outbreaks. 25 min. K. KRETSINGER	Target outcomes:	
	 Ongoing and upcoming measles and rubella policy and strategic work. 10 min. K. O'BRIEN	1. SAGE is informed of the current status of measles outbreaks and WHO response efforts.	
	Discussion: 25 min.	2. SAGE provides feedback on current WHO plan for upcoming measles rubella strategic work and addressing policy needs.	
14:05	Break	Break	30 min.
14:35	Update on COVID-19 vaccine development– Session 3		45 min.
	 Status of vaccine development. A-M. Henao Restrepo. WHO. 30 min.		
	Discussion: 15 min.		
15:20	Break	Break	15 min.
15:35	Update on Ebola - Session 4	FOR INFORMATION	30 min.
	 Situation update DRC. A. Diallo. WHO. 20 min.	Update on the Ebola epidemic in DRC, on vaccine use and safety reports, and other vaccine developments.	
	Analysis of DRC data in terms of effectiveness of ring vaccination on disease transmission. R. PETO. University of Oxford. 10 min.		
	Note: The presentation from R. Peto is not included as NEJM article currently in press		
	Discussion: 10 min.		
16:05	End of Day		

Wednesday 01 April 2020

10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	Polio - Session 5	FOR DISCUSSION AND DECISION	2h 30 min.
	 <p>Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 15 min.</p> <p>Questions: 5min.</p>	SAGE will be informed on the current status of the polio eradication program; revised strategies to respond to cVDPV outbreaks; and nOPV2 development.	
	 <p>Update on cVDPV2 epidemiology and overview of the new cVDPV2 outbreak response strategy focusing on tOPV and IPV use. O. MACH. WHO. 15 min.</p> <p>Questions: 5 min.</p>	SAGE will be asked to review and consider for endorsement:	
	 <p>Update on nOPV2 development:</p> <ul style="list-style-type: none"> • Summary of nOPV2 clinical data. A. BANDYOPADHYAY. BMGF. 15 min. 	<ul style="list-style-type: none"> • Policy implications of the new cVDPV2 outbreak response strategy (tOPV and IPV use) • Framework for initial use of nOPV2. 	
	 <ul style="list-style-type: none"> • Framework for initial-use of nOPV2 under Emergency Use Listing (EUL). G. MACKLIN. WHO. 15 min. <p>Discussion: 30 min.</p>		
	 <p>Report from SAGE Polio Working Group including recommendations for regions considering switch to IPV only schedules. I. JANI. SAGE Member. 20 min.</p> <p>Discussion: 30 min.</p>		
13:30	Break	Break	30 min.
14:00	IA2030 Monitoring and Evaluation framework - Session 6	FOR DISCUSSION	1h
	 <p>GVAP lessons learned and implications for the IA 2030 ME&A Framework. N. Arora. SAGE DoV Working Group. 5 min.</p> <p>Presentation on the aims and principles of IA2030 Monitoring, Evaluation & Action (ME&A) Framework, its development process and the Strategic Priority Goals and Objectives. A. Lindstrand. WHO. 15 min.</p> <p>Possible links of IA2030 ME&A Framework to Governance & Accountability mechanisms. K. O'Brien. WHO. 5 min.</p> <p>Questions to SAGE. A. Lindstrand. WHO. 5 min.</p> <p>Discussion: 30 min.</p>	<p>1. Share updates from the IA2030 M&E Task Force, including:</p> <ul style="list-style-type: none"> • Aims and principles of IA2030 Monitoring, Evaluation & Action (ME&A) Framework • IA2030 ME&A Framework development process • Revised IA2030 Strategic Priority Goals and Objectives • Possible links of IA2030 ME&A Framework to Governance & Accountability mechanisms • How GVAP lessons learned inform development of the IA 2030 ME&A Framework <p>2. Receive feedback from SAGE on:</p> <ul style="list-style-type: none"> • IA2030 ME&A Framework development process • Options for development of IA2030 ME&A Framework indicators and targets • Possible links of IA2030 ME&A Framework to Governance & Accountability mechanisms 	
15:00	Break	Break	15 min.

as of 30 March 2020

15:15	Global Vaccine Safety Blueprint 2.0 - Session 7	FOR DISCUSSION AND DECISION	1h
	Introduction. K. JOHANSEN. SAGE member. 5 min.	For revision and endorsement of the Global Vaccine Safety Blueprint 2.0	
	 Global Vaccine Safety Blueprint 2.0. E. Asturias-D. Salmon. (TBC). 15 min.	Questions to SAGE proposed by GACVS:	
	Discussion: 40 min.	<ol style="list-style-type: none">1. What strategic shift could be made to move from GVS1.0 to GVS2.0?2. Are there strategies for identifying resources and mechanisms for finding funds without using those reserved for vaccination?3. What are the recommendations for moving forward, including possible adjustments to the Global Vaccine Safety Initiative?	
16:15	End of the day		

Thursday, 02 April 2020

12:00	Closed SAGE meeting	Recap of day 2. Other important discussion items.	2h
14:00	End of the meeting		